UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

MicroRNAs: Allies or Foes in erythropoiesis?

Journal of cellular physiology, 2012-01, Vol.227 (1), p.7-13

2012

Volltextzugriff (PDF)

Deletion of Dicer in late erythroid cells results in impaired stress erythropoiesis in mice

Experimental hematology, 2014-10, Vol.42 (10), p.852-856.e1

2014

Volltextzugriff (PDF)

FLVCR is necessary for erythroid maturation, may contribute to platelet maturation, but is dispensable for normal hematopoietic stem cell function

Blood, 2013-10, Vol.122 (16), p.2903-2910

2013

Volltextzugriff (PDF)

Transcriptional regulation of miR-10a/b by TWIST-1 in myelodysplastic syndromes

Haematologica (Roma), 2013-03, Vol.98 (3), p.414-419

2013

Volltextzugriff (PDF)

The KDM2B- let-7b -EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapy

PloS one, 2014-09, Vol.9 (9), p.e107817

2014

Volltextzugriff (PDF)

Protein-tyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction

Molecular and cellular biochemistry, 1998-05, Vol.182 (1-2), p.101-108

1998

Volltextzugriff (PDF)

Combination therapy with the oncolytic virus CF33-CD19 and blinatumomab for the treatment of advanced solid tumors

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.TPS2687-TPS2687

2024

Volltextzugriff (PDF)

A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC-Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma

Blood, 2022-11, Vol.140 (Supplement 1), p.10327-10328

2022

Volltextzugriff (PDF)

Oncolytic virus CF33-hNIS monotherapy for the treatment of gastrointestinal (GI) malignancies

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.749-749

2024

Volltextzugriff (PDF)

Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma

Blood, 2022-11, Vol.140 (Supplement 1), p.4586-4587

2022

Volltextzugriff (PDF)

JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)

Blood, 2018-11, Vol.132 (Supplement 1), p.957-957

2018

Volltextzugriff (PDF)

A phase Ib study of atezolizumab (atezo) alone or in combination with lenalidomide or pomalidomide and/or daratumumab in patients (pts) with multiple myeloma (MM)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS8053-TPS8053

2017

Volltextzugriff (PDF)

Distinct Patterns of PD-L1 and PD-L2 Expression By Tumor and Non-Tumor Cells in Patients with MM, MDS and AML

Blood, 2016-12, Vol.128 (22), p.1340-1340

2016

Volltextzugriff (PDF)

Evidence of Targetable Immune Dysfunction in the Bone Marrow of Patients with Intermediate/High-Risk Myelodysplastic Syndrome Refractory to Hypomethylating Agents

Blood, 2017-12, Vol.130, p.4241-4241

2017

Volltextzugriff (PDF)

Regulation of Growth Factor-Induced Signaling by Protein-Tyrosine-Phosphatases

Experimental biology and medicine (Maywood, N.J.), 1997-10, Vol.216 (1), p.1-20

1997

Volltextzugriff (PDF)

The Jumanjii Histone Demethylase KDM2B controls EZH2 Expression In Myelodysplastic Syndromes (MDS) Via Mir Let-7b (let7b), a Pathway That Is Bypassed By The Histone Methylation Inhibitor DZNep

Blood, 2013-11, Vol.122 (21), p.1543-1543

2013

Volltextzugriff (PDF)

Safety and Clinical Activity of Atezolizumab (Anti-PDL1) in Combination with Obinutuzumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Blood, 2015-12, Vol.126 (23), p.5104-5104

2015

Volltextzugriff (PDF)

Abstract CT182: Oncolytic virus CF33-hNIS for the treatment of advanced cancer

Cancer research (Chicago, Ill.), 2024-04, Vol.84 (7_Supplement), p.CT182-CT182

2024

Volltextzugriff (PDF)

FLVCR Deletion Does Not Impact Normal Hematopoietic Stem Cell Function but Is Necessary for Erythroid and T-Cell Maturation and Enhances Platelet Formation

Blood, 2011-11, Vol.118 (21), p.2363-2363

2011

Volltextzugriff (PDF)

Tigit, CD226 and PD-L1/PD-1 Are Highly Expressed By Marrow-Infiltrating T Cells in Patients with Multiple Myeloma

Blood, 2016-12, Vol.128 (22), p.2102-2102

2016

Volltextzugriff (PDF)

Insulin-Induced Mitogen-Activated Protein (MAP) Kinase Phosphatase-1 (MKP-1) Attenuates Insulin-Stimulated MAP Kinase Activity: A Mechanism for the Feedback Inhibition of Insulin Signaling

Molecular endocrinology (Baltimore, Md.), 1997-09, Vol.11 (10), p.1532-1543

1997

Volltextzugriff (PDF)

Why Do Erythroid Cells Need to Export Heme?

Blood, 2011-11, Vol.118 (21), p.SCI-24-SCI-24

2011

Volltextzugriff (PDF)

Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease

The Journal of immunology (1950), 1995-07, Vol.155 (2), p.585-593

1995

Volltextzugriff (PDF)

Interferon-γ Suppresses T-Cell Proliferation to Mitogen Via the Nitric Oxide Pathway During Experimental Acute Graft-Versus-Host Disease

Blood, 1996-08, Vol.88 (3), p.1113-1121

1996

Volltextzugriff (PDF)

The KDM2B- Let-7b -EZH2 Axis in Myelodysplastic Syndromes as a Target for Combined Epigenetic Therapy: e107817

PloS one, 2014-09, Vol.9 (9)

2014

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(34)

Publikationsform

Sprache

Englisch
(41)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

MicroRNAs: Allies or Foes in erythropoiesis?

Deletion of Dicer in late erythroid cells results in impaired stress erythropoiesis in mice

FLVCR is necessary for erythroid maturation, may contribute to platelet maturation, but is dispensable for normal hematopoietic stem cell function

Transcriptional regulation of miR-10a/b by TWIST-1 in myelodysplastic syndromes

The KDM2B- let-7b -EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapy

Protein-tyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction

Combination therapy with the oncolytic virus CF33-CD19 and blinatumomab for the treatment of advanced solid tumors

A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC-Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma

Oncolytic virus CF33-hNIS monotherapy for the treatment of gastrointestinal (GI) malignancies

Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma

JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)

A phase Ib study of atezolizumab (atezo) alone or in combination with lenalidomide or pomalidomide and/or daratumumab in patients (pts) with multiple myeloma (MM)

Distinct Patterns of PD-L1 and PD-L2 Expression By Tumor and Non-Tumor Cells in Patients with MM, MDS and AML

Evidence of Targetable Immune Dysfunction in the Bone Marrow of Patients with Intermediate/High-Risk Myelodysplastic Syndrome Refractory to Hypomethylating Agents

Regulation of Growth Factor-Induced Signaling by Protein-Tyrosine-Phosphatases

The Jumanjii Histone Demethylase KDM2B controls EZH2 Expression In Myelodysplastic Syndromes (MDS) Via Mir Let-7b (let7b), a Pathway That Is Bypassed By The Histone Methylation Inhibitor DZNep

Safety and Clinical Activity of Atezolizumab (Anti-PDL1) in Combination with Obinutuzumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Abstract CT182: Oncolytic virus CF33-hNIS for the treatment of advanced cancer

FLVCR Deletion Does Not Impact Normal Hematopoietic Stem Cell Function but Is Necessary for Erythroid and T-Cell Maturation and Enhances Platelet Formation

Tigit, CD226 and PD-L1/PD-1 Are Highly Expressed By Marrow-Infiltrating T Cells in Patients with Multiple Myeloma

Insulin-Induced Mitogen-Activated Protein (MAP) Kinase Phosphatase-1 (MKP-1) Attenuates Insulin-Stimulated MAP Kinase Activity: A Mechanism for the Feedback Inhibition of Insulin Signaling

Why Do Erythroid Cells Need to Export Heme?

Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease

Interferon-γ Suppresses T-Cell Proliferation to Mitogen Via the Nitric Oxide Pathway During Experimental Acute Graft-Versus-Host Disease

The KDM2B- Let-7b -EZH2 Axis in Myelodysplastic Syndromes as a Target for Combined Epigenetic Therapy: e107817

Suchergebnisse filtern